http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2371748-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa6a8dbd6467e560cd0ec019fe7d722a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate | 2000-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b94397f75fea9f4837f0b6d26ec9af9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6e9429a842cf803e846897046086e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb0b681de2c8983b29d615bdaa9a286b |
| publicationDate | 2002-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2371748-A |
| titleOfInvention | HMG-COA reductase inhibitor extended release formulation |
| abstract | Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (T<SB>max</SB>) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed. |
| priorityDate | 1999-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.